Trial Profile

Effects of Anti-TSLP on Airway Hyperresponsiveness and Mast Cell Phenotype in Asthma - A Randomized Double-blind, Placebo-controlled Trial of MEDI9929

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 May 2021 Primary endpoint has been met. (Supportive primary objective 1: Mannitol test negative in response to treatment with MEDI9929 in patients with asthma)
28 May 2021 Primary endpoint has not been met. (Supportive primary objective 3: Decrease in airway hyperresponsiveness to mannitol in response to treatment with MEDI9929 in patients with asthma)
28 May 2021 Primary endpoint of decrease in airway hyperresponsiveness to mannitol in response to treatment with MEDI9929 in patients with asthma has not been met, according to results published in the European Respiratory Journal.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com